Ratify (Alliance 10603): Prognostic impact of FLT3 tyrosine kinase domain (TKD) and NPM1 mutation status in patients with newly diagnosed acute myeloid leukemia (AML) treated with midostaurin or placebo plus standard chemotherapy Meeting Abstract
| Authors: | Voso, M. T.; Larson, R. A.; Prior, T.; Marcucci, G.; Jones, D.; Krauter, J.; Heuser, M.; Lavorgna, S.; Nomdedeu, J.; Geyer, S. M.; Klisovic, R.; Wei, A. H.; Sierra, J.; Sanz, M. A.; Brandwein, J. M.; de Witte, T. M.; Jansen, J. H.; Niederweiser, D.; Appelbaum, F. R.; Medeiros, B. C.; Tallman, M. S.; Schlenk, R. F.; Ganser, A.; Amadori, S.; Cheng, Y.; Gathmann, I.; Tiecke, E.; Thiede, C.; Dohner, K.; Dohner, H.; Stone, R. M.; Bloomfield, C. D.; Lo-Coco, F. |
| Abstract Title: | Ratify (Alliance 10603): Prognostic impact of FLT3 tyrosine kinase domain (TKD) and NPM1 mutation status in patients with newly diagnosed acute myeloid leukemia (AML) treated with midostaurin or placebo plus standard chemotherapy |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837607274 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-114318 |
| Notes: | Meeting Abstract: 2668 -- Source: Wos |
